Last reviewed · How we verify
Neuroleptic-induced Parkinsonism
Approved treatments
- Dexbenzetimide
Dexbenzetimide works by blocking the M2 muscarinic acetylcholine receptor, which helps to regulate muscle contractions and other bodily functions.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Neuroleptic-induced Parkinsonism patent landscape — cliff calendar, originator estates, attackable patents
- Neuroleptic-induced Parkinsonism treatment landscape brief
- Neuroleptic-induced Parkinsonism treatment updates RSS
Frequently asked questions about Neuroleptic-induced Parkinsonism
What drugs treat Neuroleptic-induced Parkinsonism?
Tracked treatments include Dexbenzetimide.
What is the treatment for Neuroleptic-induced Parkinsonism?
Standard treatment for Neuroleptic-induced Parkinsonism includes Dexbenzetimide. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Neuroleptic-induced Parkinsonism patent cliff · Neuroleptic-induced Parkinsonism CI report
- Treatment: Dexbenzetimide
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing